Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.
about
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistanceA peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutantsAMF1 (GPS2) modulates p53 transactivationThe C terminus of p53 family proteins is a cell fate determinantTreatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptideCP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activityChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingSCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53Definition of the p53 functional domains necessary for inducing apoptosis.Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.Strategies for manipulating the p53 pathway in the treatment of human cancer.Hsp70 interactions with the p53 tumour suppressor protein.Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.P53: an ubiquitous target of anticancer drugs.Regulation of senescence in cancer and aging.Does p53 affect organismal aging?Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.Awakening guardian angels: drugging the p53 pathway.Insights into aging obtained from p53 mutant mouse models.Apoptosis-based therapies and drug targets.Dissecting p53-dependent apoptosis.Strategies for therapeutic targeting of the p53 pathway in cancer.Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.Reactivation of mutant p53: molecular mechanisms and therapeutic potential.Targeting protein-protein interactions: lessons from p53/MDM2.Cutting-edge apoptosis-based therapeutics: a panacea for cancer?[The use of p53 as a tool for human cancer therapy].Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.Targeting p53 for enhanced radio- and chemo-sensitivity.Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.Therapeutic strategies for head and neck cancer based on p53 status.Tp53 and its potential therapeutic role as a target in bladder cancer.Evidence of a prion-like transmission of p53 amyloid in Saccharomyces cerevisiae.Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ.Characterization of the cell death induced by cadmium in HaCaT and C6 cell lines.p53 requires an intact C-terminal domain for DNA binding and transactivation.Evidence for a distinct inhibitory factor in the regulation of p53 functional activity.
P2860
Q23920106-6F56C56C-CA36-4A89-AFDD-518A7727EAF3Q24530763-1F6842E7-D6D4-4A32-84EA-56C748838536Q24550865-7001A27E-5561-46CA-A77C-B290E12A87CFQ24556628-3B7871B7-27AA-4C10-AC4E-9F9146401CE4Q24796110-120833F3-5609-4A4E-8A7E-E021FC35D833Q24800091-FD8A48B0-13E6-4E4C-9A63-328E13821572Q26863501-2C84B815-B159-4B12-997C-918E81A9B736Q33795918-3D39068F-FF9F-4308-921D-E4D199A939FCQ33917509-B048CF05-DF32-421A-84AB-0D3016C006F1Q34035601-2A9CC3E8-A065-4AD5-AAFA-765FD84FE1BDQ34076012-9454E833-4729-4858-BBEB-8ECCC586C8DCQ34353830-C8C180BA-D9D7-4BDE-A4F2-F31590457C36Q34498137-4708DA70-B03E-42BE-BB1C-D46275FFCEC3Q34539978-E20B5868-06AF-4570-B900-453A1428A77EQ34665706-4BBC3E59-4E52-4CD7-80A0-B8A445375EAAQ34736706-508F97F5-8065-4B09-9D05-9F51DAAEF840Q34740058-A0877987-691B-421B-8CF1-EC23949FEAA2Q35014385-AC1FDA18-4A44-4DA5-BFAF-FBB140C06D37Q35832896-0F061184-95C6-4764-9FBC-8D832F5D2DE3Q36017772-0D50700D-BCAD-406F-80CF-8926AD4079D0Q36423933-C783F0B5-EA54-4202-85DB-0735665191B6Q36430162-D79EFEEC-925A-4103-A3D1-2538719D3180Q36545877-5768A7B5-D8CB-4426-9DDA-B66720E5E2B4Q36777373-6AFAF7E5-6C09-4B95-948C-0C5D196671DAQ36788125-F88EBE5F-1D82-4963-B1E2-7C17B41A1B25Q36951942-B60D2E35-E991-4920-80A0-CDF5D2DBA45AQ37081504-A0671611-939E-4E0D-8FAA-B41510C7E7F3Q37186976-8EC8B9A4-941E-44B1-852A-0ED9B250DB62Q37406067-96239BC6-A983-40C6-BBA4-C1D409FA4AC1Q37564522-F80F7B57-76DE-444E-9C02-B95378917598Q37678297-EC2DFE5D-6D5D-42E6-BD4D-BF7AEEF565C4Q38042630-26701F9A-42AF-402A-A8B9-932941AE8F88Q38436074-07958FA7-BDE4-430B-9594-D4B164623CF9Q38718360-7F0E5FB4-F294-40D2-BF0A-047A1C5B6686Q38948352-C1DD2C54-D361-416E-8040-9D6AF4B3FA53Q38977312-14654A9E-5B13-47BF-B63C-6B13AD34BAF1Q39239566-04019247-3CF0-4922-8FA9-F3136C5ED8B8Q40009222-F9D75C30-0F83-4A59-A7E9-009B54ABC961Q40715545-3F6189D6-ED22-4FA7-B92B-E605DD79D278Q40802430-A428F062-56DB-46DC-86A6-C03EE963AFB3
P2860
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Reactivation of mutant p53 thr ...... peptide with the core domain.
@en
Reactivation of mutant p53 thr ...... peptide with the core domain.
@nl
type
label
Reactivation of mutant p53 thr ...... peptide with the core domain.
@en
Reactivation of mutant p53 thr ...... peptide with the core domain.
@nl
prefLabel
Reactivation of mutant p53 thr ...... peptide with the core domain.
@en
Reactivation of mutant p53 thr ...... peptide with the core domain.
@nl
P2093
P2860
P356
P1476
Reactivation of mutant p53 thr ...... l peptide with the core domain
@en
P2093
L Ryabchenko
P2860
P304
P356
10.1128/MCB.19.5.3395
P407
P577
1999-05-01T00:00:00Z